Search

Your search keyword '"Michelle Remiao Ugolini Lopes"' showing total 2 results
Start Over Author "Michelle Remiao Ugolini Lopes"
2 results on '"Michelle Remiao Ugolini Lopes"'

1. Immunogenicity and safety of primary fractional-dose yellow fever vaccine in autoimmune rheumatic diseases.

Author

Adriana Coracini Tonacio, Tatiana do Nascimento Pedrosa, Eduardo Ferreira Borba, Nadia Emi Aikawa, Sandra Gofinet Pasoto, Júlio Cesar Rente Ferreira Filho, Marília Mantovani Sampaio Barros, Elaine Pires Leon, Suzete Cleusa Ferreira Spina Lombardi, Alfredo Mendrone Junior, Adriana de Souza Azevedo, Waleska Dias Schwarcz, Ricardo Fuller, Emily Figueiredo Neves Yuki, Michelle Remião Ugolini Lopes, Rosa Maria Rodrigues Pereira, Percival Degrava Sampaio Barros, Danieli Castro Oliveira de Andrade, Ana Cristina de Medeiros-Ribeiro, Julio Cesar Bertacini de Moraes, Samuel Katsuyuki Shinjo, Renata Miossi, Alberto José da Silva Duarte, Marta Heloisa Lopes, Esper Georges Kallás, Clovis Artur Almeida da Silva, and Eloisa Bonfá

Subjects
Arctic medicine. Tropical medicine, RC955-962, Public aspects of medicine, RA1-1270
Abstract

BackgroundBrazil faced a yellow fever(YF) outbreak in 2016-2018 and vaccination was considered for autoimmune rheumatic disease patients(ARD) with low immunosuppression due to YF high mortality.ObjectiveThis study aimed to evaluate, prospectively for the first time, the short-term immunogenicity of the fractional YF vaccine(YFV) immunization in ARD patients with low immunossupression.Methods and resultsA total of 318 participants(159 ARD and 159 age- and sex-matched healthy controls) were vaccinated with the fractional-dose(one fifth) of 17DD-YFV. All subjects were evaluated at entry(D0), D5, D10, and D30 post-vaccination for clinical/laboratory and disease activity parameters for ARD patients. Post-vaccination seroconversion rate(83.7%vs.96.6%, p = 0.0006) and geometric mean titers(GMT) of neutralizing antibodies[1143.7 (95%CI 1012.3-1292.2) vs.731 (95%CI 593.6-900.2), p0.05).ConclusionFractional-dose 17DD-YF vaccine in ARD patients resulted in a high rate of seroconversion rate(>80%) but lower than controls, with a longer but less intense viremia. This vaccine was immunogenic, safe and did not induce flares in ARD under low immunosuppression and may be indicated in YF outbreak situations and for patients who live or travel to endemic areas.Trial registrationThis clinical trial was registered with Clinicaltrials.gov (#NCT03430388).

Published
2021
Full Text
View/download PDF

2. Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases

Author

Nádia Emi Aikawa, Leonard de Vinci Kanda Kupa, Ana Cristina Medeiros-Ribeiro, Carla Goncalves Schahin Saad, Emily Figueiredo Neves Yuki, Sandra Gofinet Pasoto, Priscila Tagliaferro Rojo, Rosa Maria Rodrigues Pereira, Samuel Katsuyuki Shinjo, Percival Degrava Sampaio-Barros, Danieli Castro Oliveira Andrade, Ari Stiel Radu Halpern, Ricardo Fuller, Fernando Henrique Carlos Souza, Lissiane Karine Noronha Guedes, Ana Paula Luppino Assad, Julio Cesar Bertacini de Moraes, Michelle Remiao Ugolini Lopes, Victor Adriano de Oliveira Martins, Lorena Betancourt, Carolina Torres Ribeiro, Lucas Peixoto Sales, Isabela Maria Bertoglio, Virginia Lucia Nazario Bonoldi, Renata Lys Pinheiro Mello, Gustavo Guimaraes Moreira Balbi, Ana Marli Christovam Sartori, Leila Antonangelo, Clóvis Artur Silva, and Eloisa Bonfa

Subjects
Adult, Male, COVID-19 Vaccines, SARS-CoV-2, Immunology, COVID-19, Antibodies, Viral, General Biochemistry, Genetics and Molecular Biology, Autoimmune Diseases, Immunogenicity, Vaccine, Rheumatology, Immunoglobulin G, Rheumatic Diseases, Humans, Prednisone, Immunology and Allergy, Female
Abstract

ObjectiveTo determine the immunogenicity of the third dose of CoronaVac vaccine in a large population of patients with autoimmune rheumatic diseases (ARD) and the factors associated with impaired response.MethodsAdult patients with ARD and age-balanced/sex-balanced controls (control group, CG) previously vaccinated with two doses of CoronaVac received the third dose at D210 (6 months after the second dose). The presence of anti-SARS-CoV-2 S1/S2 IgG and neutralising antibodies (NAb) was evaluated previously to vaccination (D210) and 30 days later (D240). Patients with controlled disease suspended mycophenolate mofetil (MMF) for 7 days or methotrexate (MTX) for 2 weekly doses after vaccination.ResultsARD (n=597) and CG (n=199) had comparable age (p=0.943). Anti-S1/S2 IgG seropositivity rates significantly increased from D210 (60%) to D240 (93%) (pConclusionsWe provide novel data on a robust response to the third dose of CoronaVac in patients with ARD, even in those with prevaccination COVID-19 seronegative status. Drugs implicated in reducing immunogenicity after the regular two-dose regimen were associated with non-responsiveness after the third dose, except for MTX.Trial registration numberNCT04754698.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results